No. medications 5.7 ± 0.6 5.7 ± 0.6 5.7 ± 0.6 5.7 ± 0.6 5.5 ± 0.7 5.3 ± 0.9 p = 0.15 No. med. classes 5.7 ± 0.7 5.7 ± 0.7 5.7 ± 0.7 5.7 ± 0.7 5.5 ± 0.7 5.3 ± 0.9 p = 0.15 WDE 4.2 ± 0.5 4.4 ± 0.6 4.4 ± 0.6 4.4 ± 0.6 4.3 ± 0.6 4.3 ± 0.8 p = 0.98 All participants No. medications 5.7 ± 0.3 5.7 ± 0.3 5.1 ± 0.5 5.1 ± 0.4 4.9 ± 0.4 5.1 ± 0.5 p = 0.01 (n=15)
No. med. classes 5.6 ± 0.3 5.6 ± 0.3 5.1 ± 0.5 5.1 ± 0.4 4.9 ± 0.4 5.1 ± 0.5 p = 0.01 WDE 4.7 ± 0.5 4.8 ± 0.5 4.2 ± 0.6 4.2 ± 0.6 4.2 ± 0.6 4.2 ± 0.6 p = 0.01
Supplemental Table 3
A list of the exclusion criteria used in this first in man trial. given that SBD was a pre-existing disease in this patient and the apnea-hypopnea index increased from 20 events/hr at baseline to 74 events/hr three months post-carotid body removal, worsening Sleep Disordered Breathing (SBD) should be noted as an adverse event. The event is noted as resolved since the patient was treated with continuous positive airway pressure (CPAP) after the increase in SBD was found.
** Since difficult to control blood pressure was a reason to participate in the trial, this prolonged hospitalization, which followed unilateral carotid body removal could only be judged to be possibly related to the carotid body removal procedure or treatment.
*** Since difficult to control blood pressure was a reason to participate in the trial, this prolonged hospitalization, which had no temporal relationship to unilateral carotid body removal was judged to be unlikely to be related to the carotid body removal procedure or treatment. Moreover, the patient had been hospitalized prior to the study for difficult to control blood pressure.
